Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC
Masahiro Tsuboi, Roy S. Herbst, Thomas John, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 2, pp. 137-147
Closed Access | Times Cited: 332

Showing 1-25 of 332 citing articles:

Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
David Planchard, Pasi A. Jänne, Ying Cheng, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 21, pp. 1935-1948
Closed Access | Times Cited: 248
Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
Yi‐Long Wu, Rafał Dziadziuszko, Jin Seok Ahn, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 14, pp. 1265-1276
Closed Access | Times Cited: 133
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
Giannis Mountzios, Jordi Remón, Lizza E.L. Hendriks, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 10, pp. 664-677
Closed Access | Times Cited: 106
Lung cancer in patients who have never smoked — an emerging disease
Jaclyn LoPiccolo, Alexander Gusev, David C. Christiani, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 2, pp. 121-146
Open Access | Times Cited: 69
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer
Pasi A. Jänne, David Planchard, Kunihiko Kobayashi, et al.
Journal of Clinical Oncology (2023) Vol. 42, Iss. 7, pp. 808-820
Open Access | Times Cited: 54
Non-small-cell lung cancer
Lizza E.L. Hendriks, Jordi Remón, C. Faivre‐Finn, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 43
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial
Martin Schüler, Kristof Cuppens, Till Plönes, et al.
Nature Medicine (2024) Vol. 30, Iss. 6, pp. 1602-1611
Open Access | Times Cited: 29
Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer
Jonathan Spicer, Tina Cascone, Murry W. Wynes, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 10, pp. 1373-1414
Open Access | Times Cited: 25
Parkinson’s Disease is Predominantly a Genetic Disease
Shen‐Yang Lim, Christine Klein
Journal of Parkinson s Disease (2024) Vol. 14, Iss. 3, pp. 467-482
Open Access | Times Cited: 24
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
Jonathan Spicer, Marina Chiara Garassino, Heather A. Wakelee, et al.
The Lancet (2024) Vol. 404, Iss. 10459, pp. 1240-1252
Closed Access | Times Cited: 22
Challenges and controversies in resectable non-small cell lung cancer: a clinician’s perspective
Ilias Houda, Chris Dickhoff, Carin A. Uyl‐de Groot, et al.
The Lancet Regional Health - Europe (2024) Vol. 38, pp. 100841-100841
Open Access | Times Cited: 20
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study
Amin H. Nassar, So Yeon Kim, Jacqueline V. Aredo, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 6, pp. 928-940
Closed Access | Times Cited: 19
Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC
Yixin Zhou, Anlin Li, Hui Yu, et al.
JAMA Network Open (2024) Vol. 7, Iss. 3, pp. e241285-e241285
Open Access | Times Cited: 19
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study
Collin M. Blakely, Anatoly Urisman, Matthew A. Gubens, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 26, pp. 3105-3114
Open Access | Times Cited: 17
Regulating chemoresistance and cancer stemness: the CDH17-YAP pathway in distinct cellular states of lung cancer CTC clusters
Zujun Que, Dan Qi, Yun Jung Yang, et al.
Cellular & Molecular Biology Letters (2025) Vol. 30, Iss. 1
Open Access | Times Cited: 2
Management of locally advanced non‐small cell lung cancer: State of the art and future directions
Da Miao, Jing Zhao, Ying Han, et al.
Cancer Communications (2023) Vol. 44, Iss. 1, pp. 23-46
Open Access | Times Cited: 41
Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives
Jay M. Lee, Ciaran McNamee, Eric M. Toloza, et al.
Journal of Thoracic Oncology (2023) Vol. 18, Iss. 11, pp. 1458-1477
Open Access | Times Cited: 37
New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe
Ilias Houda, Chris Dickhoff, Carin A. Uyl‐de Groot, et al.
The Lancet Regional Health - Europe (2024) Vol. 38, pp. 100840-100840
Open Access | Times Cited: 15
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104)
Chao Zhang, Yuxuan Sun, Dingcheng Yi, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 7, pp. 101615-101615
Open Access | Times Cited: 15
The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer
Elizabeth G. Dunne, Cameron N. Fick, James M. Isbell, et al.
The Annals of Thoracic Surgery (2024) Vol. 118, Iss. 1, pp. 119-129
Closed Access | Times Cited: 13
ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung Cancer
Aakash Desai, Tadana A. Vázquez, Keishla M. Arce, et al.
Cancers (2024) Vol. 16, Iss. 5, pp. 940-940
Open Access | Times Cited: 13
Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma
Jiaqi Liang, Guoshu Bi, Qihai Sui, et al.
Cell Reports (2024) Vol. 43, Iss. 2, pp. 113771-113771
Open Access | Times Cited: 12
Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer
Christopher H. Grant, Misako Nagasaka
Cancer Treatment Reviews (2024) Vol. 126, pp. 102724-102724
Open Access | Times Cited: 12
Recent advances in lung cancer research: unravelling the future of treatment
Luca Bertolaccini, Monica Casiraghi, Clarissa Uslenghi, et al.
Updates in Surgery (2024) Vol. 76, Iss. 6, pp. 2129-2140
Closed Access | Times Cited: 12
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 trial
Jean-Yves Blay, Quentin Devin, Florence Duffaud, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 9, pp. 1163-1175
Closed Access | Times Cited: 12
Page 1 - Next Page

Scroll to top